Dulaglutide: Evidence, Safety, Dosing, and How It Compares

Dulaglutide, also known by the brand name Trulicity, is a once-weekly GLP-1 receptor agonist studied mainly in people with type 2 diabetes. This guide explains how it works, what human trials show, common safety considerations, dosing concepts, and how to discuss legitimate treatment options with a licensed clinician.

What it is

Dulaglutide is a GLP-1 receptor agonist, a drug class that acts on the same receptor pathway as the body’s natural incretin hormone GLP-1. In labeling, dulaglutide is given by subcutaneous injection on a once-weekly schedule 13.

Dulaglutide, Trulicity, and the GLP-1 receptor agonist class

Dulaglutide is the generic name. Trulicity is a brand name. The class is GLP-1 receptor agonist, sometimes called an incretin mimetic because it copies part of the signaling pattern of incretin hormones involved in blood sugar control 13.

If you are new to the class, our plain-English guide to what GLP-1 medications are explains the shared pathway. Dulaglutide belongs in that family, but it is not the same medication as semaglutide, Ozempic, Wegovy, tirzepatide, Mounjaro, or Zepbound.

Who this guide is for

This guide is for people trying to understand dulaglutide as a medication name, a GLP-1 option, or a comparator to other incretin drugs. Most retrieved human trial evidence for dulaglutide is in people with type 2 diabetes, including cardiovascular outcome and head-to-head studies 1, 6.

Mechanism of action

Dulaglutide works by activating the GLP-1 receptor, a signaling pathway involved in insulin response, glucagon regulation, appetite, and gastric emptying. A registered clinical study specifically evaluated LY2189265, the development code for dulaglutide, and gastric emptying in people with type 2 diabetes 14.

GLP-1 receptor signaling in plain English

After a meal, GLP-1 helps the body match insulin release to rising blood sugar. A GLP-1 receptor agonist turns on that receptor for longer than natural GLP-1, which is one reason these drugs have been studied in type 2 diabetes 13.

Blood sugar, insulin response, appetite, and gastric emptying concepts

The main concepts are insulin secretion when glucose is present, lower glucagon signaling, slower stomach emptying, and appetite effects. These mechanisms can also explain side effects: slower gastric emptying can contribute to nausea or fullness, and diabetes medication combinations can affect hypoglycemia risk 13.

For a broader explanation of GLP-1 peptides and incretin biology, see our guide to GLP-1 peptides. It covers the class in more detail without treating all GLP-1 medicines as interchangeable.

Evidence

Evidence grade: A. The retrieved PubMed set includes more than two human randomized controlled trials of dulaglutide or dulaglutide comparator arms, including REWIND and SUSTAIN 7 1, 6.

A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.

What the grade does and does not mean

An A grade means there are multiple human randomized trials in the retrieved set. It does not mean dulaglutide is the right medication for a specific person, and it does not remove the need to weigh gastrointestinal adverse effects, hypoglycemia risk with some diabetes drugs, pancreatitis warnings, gallbladder concerns, dehydration-related kidney injury risk, and the thyroid C-cell tumor warning with a clinician 13.

Major outcomes studied in type 2 diabetes

The REWIND trial was a double-blind, randomized, placebo-controlled trial studying dulaglutide and cardiovascular outcomes in people with type 2 diabetes 1. Other registered dulaglutide studies include a phase 4 study in Japanese participants and a phase 3 study in participants with type 2 diabetes on insulin therapy 15, 16.

Comparisons with semaglutide, tirzepatide, and other incretin medications

SUSTAIN 7 directly compared once-weekly semaglutide and dulaglutide in patients with type 2 diabetes in a randomized phase 3b trial 6. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has also been compared with dulaglutide in clinical trial settings in type 2 diabetes 2, 4.

Newer incretin-related drugs are not dulaglutide equivalents. Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, orforglipron, an oral GLP-1 receptor agonist, and mazdutide have randomized trial evidence in type 2 diabetes populations, but they remain separate drugs with separate evidence bases 5, 8, 7.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-08.

Reported dosing ranges

Dulaglutide dosing is not one-size-fits-all. The table below reports label-based dose levels and trial contexts as sources describe them; it is not a personal dosing plan or a recommendation to start, stop, or change any medication 13.

Why dosing is not one-size-fits-all

Clinicians consider kidney function, current diabetes medications, prior gastrointestinal symptoms, hypoglycemia risk, goals of care, and warning signs before changing any GLP-1 medication. Labeling includes safety topics that can affect dosing decisions, including gastrointestinal adverse reactions and dehydration-related kidney injury risk 13.

For general education on titration language, see our guide to GLP-1 dosage for weight loss. That article explains why online calculators and fixed schedules cannot replace a licensed medical review.

Legal status

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-08. See the full legal-status tracker for every compound we follow.

Safety

Dulaglutide safety is best understood in two layers: common GLP-1 effects and less common but important warning signs. Labeling and trials support discussing gastrointestinal adverse effects, hypoglycemia risk with certain diabetes medicines, pancreatitis, gallbladder disease, kidney injury risk from dehydration, and the thyroid C-cell tumor warning 13.

Common GLP-1-related side effects

Common GLP-1-related side effects are often gastrointestinal, such as nausea, vomiting, diarrhea, abdominal discomfort, reduced appetite, or constipation. These effects make sense with the mechanism because GLP-1 signaling can slow gastric emptying and affect appetite pathways 13, 14.

Serious risks and warning signs to discuss with a clinician

Labeling includes warnings and precautions for pancreatitis, gallbladder disease, kidney injury risk related to dehydration, severe gastrointestinal disease concerns, hypoglycemia risk when used with insulin or insulin secretagogues, and thyroid C-cell tumor risk 13. Severe or persistent abdominal pain, repeated vomiting, dehydration, symptoms of low blood sugar, or neck swelling are examples of concerns that should be discussed urgently with a care team.

Who may not be a good candidate

Some people may not be good candidates for dulaglutide based on contraindications or warnings in labeling, including personal or family history tied to the thyroid C-cell tumor warning, certain endocrine tumor syndromes, serious hypersensitivity, or situations where gastrointestinal or pancreatic risk changes the risk-benefit discussion 13. A clinician also reviews pregnancy plans, diabetes medicines, prior reactions, and current symptoms before making a treatment decision.

Our GLP-1 side effects guide goes deeper on nausea, constipation, reflux, dehydration, and warning signs across the class. It is still general education, not a substitute for care from your own clinician.

Risks of unregulated supply

Research-chemical sellers, peptide marketplaces, and group buys are not medical care. Products sold as “research use only” may lack the clinician evaluation, pharmacy controls, identity checks, sterility standards, impurity testing, and follow-up that are part of legitimate medication care.

Interactions

Dulaglutide interactions matter most when they involve diabetes drugs and medicines taken by mouth. Labeling highlights hypoglycemia risk with insulin or insulin secretagogues and the possibility that delayed gastric emptying may affect absorption of oral medications 13.

Diabetes medications and low blood sugar risk

GLP-1 receptor agonists are often discussed alongside insulin, sulfonylureas, and other glucose-lowering medicines because combinations can change hypoglycemia risk. Labeling specifically calls out hypoglycemia risk when dulaglutide is used with insulin or insulin secretagogues 13.

Delayed gastric emptying and oral medications

Dulaglutide can slow gastric emptying, and a registered study evaluated the effect of LY2189265 on the speed at which food and drink leave the stomach in people with type 2 diabetes 14. Because many oral medicines depend on timing and absorption, clinicians may ask about narrow-therapeutic-index drugs, symptoms, and medication timing 13.

Surgery, procedures, and when to tell your care team

Because delayed gastric emptying can matter for anesthesia planning and procedure safety, patients should tell their care team about GLP-1 medication use before surgery or procedures. This is a care-coordination issue, not a reason to change medication without instructions from the clinician managing the procedure and the prescribing clinician 13.

How to obtain it legally

Dulaglutide should be discussed through a real medical process: a health history, medication review, contraindication screen, treatment-goal discussion, prescription decision by a licensed clinician, and pharmacy fulfillment when appropriate. A prescription decision is never guaranteed.

Clinician evaluation, prescription decision, and pharmacy fulfillment

A legitimate evaluation should review type 2 diabetes history, weight and metabolic goals, current medications, hypoglycemia risk, kidney issues, gastrointestinal symptoms, pancreatitis or gallbladder history, thyroid C-cell tumor warning factors, and pregnancy considerations. These topics line up with the mechanism and safety concerns described in labeling 13.

Why research-chemical vendors are not medical care

A website selling a vial, pen, powder, or “research” material is not the same as clinician-guided care. It does not replace a medical exam, prescription decision, pharmacist oversight, adverse-effect monitoring, or a plan for what to do if symptoms occur.

What Chia offers instead

Chia does not offer dulaglutide. For patients seeking clinician-reviewed GLP-1 care, Chia offers compounded semaglutide injection, with plans currently starting at $249/mo, and compounded tirzepatide tablets or injection, with tablet plans currently starting at $249/mo and injection plans currently starting at $299/mo. Microdosing plans are available for semaglutide and tirzepatide where clinically appropriate.

At Chia, care starts with a short online health questionnaire. A licensed US provider reviews it and prescribes only when clinically appropriate; dosing is provider-guided and adjusted over time, and patients can message the care team through the patient portal. Chia medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Compounded medications are not FDA-approved.

For broader comparisons, see our GLP-1 drugs list and our side-by-side guide to which GLP-1 may be best for weight loss. Those pages compare medications without treating brand-name drugs and compounded formulations as the same product.

How dulaglutide compares with other GLP-1 and incretin medications

Keep reading

Weight Loss

GLP-1 Peptides Explained: How They Work, Who They Help, and How to Get One

Weight Management

Retatrutide: Evidence, Safety, Dosing Studied, and Access Questions

Weight Management

Methylene Blue: Evidence, Safety, Dosing, and Access